Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC

Cancer Immunology Research

Volumn 4, Issue 5, 2016, Pages 419-430

  Gabrielson, Andrew ^a   Wu, Yunan ^b   Wang, Hongkun ^a   Jiang, Jiji ^a   Kallakury, Bhaskar ^a   Gatalica, Zoran ^c   Reddy, Sandeep ^c   Kleiner, David ^d   Fishbein, Thomas ^a   Johnson, Lynt ^a   Island, Eddie ^a   Satoskar, Rohit ^a   Banovac, Filip ^a   Jha, Reena ^a   Kachhela, Jaydeep ^a   Feng, Perry ^a   Zhang, Tiger ^a   Tesfaye, Anteneh ^a   Prins, Petra ^a   Loffredo, Christopher ^a   Marshall, John ^a   Weiner, Louis ^a   Atkins, Michael ^a   He, Aiwu Ruth ^a   more..

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

^c CARIS LIFE SCIENCES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; RECURRENCE FREE SURVIVAL; TUMOR INVASION; TUMOR THROMBUS; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; FOLLOW UP; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; ANTIGENS, CD3; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RISK FACTORS; T-LYMPHOCYTE SUBSETS;

EID: 84976622250     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0110     Document Type: Article

References (43)

1. Said A, Wells J. Management of heptocellular carcinoma. Minerva Med 2009;100:51-68.
2. Locker GY, Hamilton S, Harris J, Jessup JM, Hayes D, Bast RCJr, et al. ASCO update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
3. Sobin L, Wittekind C. TNM classification of malignant tumors . New York: Wiley-Liss; 2002.
4. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-65.
5. Chan AC, Fan ST, Cheung TT, Chok KS, Chan SC, Lo CM, et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumournode-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of arefined staging system. HPB 2013;15:439-48.
6. Lee SC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol 2014;20:3112-24.
7. Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care?Nat Rev Clin Oncol 2011;9:119-23.
8. Mlecnik B, Bindea G, Pages F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011;30:5-12.
9. Dunn GP, Old LJ, Schreiber RD. The three E's of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
10. Shankaran V, Ikeda H, White JM, Swanson PE, Old LJ, Bruce AT, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
11. Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey TL, Chouchane L, et al. An immunologic portrait of cancer. J Transl Med 2011;9:146.
12. Atreya I, Neurath MF. Immune cells in colorectal cancer: Prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 2008;8: 561-72.
13. Baier PK, Wimmenauer S, Hirsch T, von Kleist S, Keller H, Farthmann EH, et al. Analysis of the T cell receptor variability of tumor infiltrating lymphocytes in colorectal carcinomas. Tumour Biol 1998;19:205-12.
14. Diederichsen AC, Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumor cells. Cancer Immunol Immunother 2003;52:423-8.
15. Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-15.
16. Galon J, Costes A, Sanchez-Cabo F, Tranjanoski Z, Fridman WH, Pages F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
17. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007;67:1883-6.
18. Naito Y, Saito K, Shiiba K, Saigenji K, Nagura H, Ohtani H, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
19. Pages F, Berger A, Camus M, Trajanoski Z, Fridman WH, Galon J, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
20. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004;173: 945-54.
21. Kim YJ. Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. OncoImmunology 2015;3:e954868.
22. Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013;25:261-7.
23. Anitei M, Zeitoun G, Mlecnik B, Berger A, Galon J, Pages F. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res 2014;20.7:1891-9.
24. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Bruneval P, Galon J, et al. In situ cytotoxic and memory T cells predict outcome in patients with early stage colorectal cancer. J Clin Oncol 2009;27:5944-51.
25. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic b-catenin signaling prevents T cell infiltration and anti-tumor immunity. Nature 2015; 231-35.
26. Jemal A, Freddie B, Melissa M, Jacques F, Elizabeth W, David F. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
27. Parpart S, Stephanie R, Fei D, Zhao-You T, Wang X. Modulation of MiR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology 2014;60:872-83.
28. Marshall A, Alexander G. Vascular invasion leaves its mark in hepatocellular carcinoma. J Hepatol 2011;55:1174-5.
29. Thuluvath P. Vascular invasion is the most important predictor of survival in hcc, but how do we find it?J Clin Gastroenterol 2009;43:101-2.
30. Shah S, Cleary S, Greig P, Gallinger S. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007;141:330-9.
31. Coppola D, Mule J. Ectopic lymph nodes within human solid tumors. J Clin Oncol 2008;26:4369-70.
32. Dubinett S, Lee J, Sharma S, Mule J. Chemokines: can effector cells be redirected to the site of tumor?Cancer J 2010;167:325-35.
33. Spranger S, Spaapen RM, Meng Y, Ha T, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;8:200ra116.
34. Taube JM. Unleashing the immune system: PD-1 and PD-Ls in the pretreatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology 2014;11:e963413. eCollection 2014.
35. El-Khoueiry A, Ignacio M, Crocenzi T, Sangro B. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015;33suppl; abstr LBA101.
36. Zhang B, Sun T, Xue L, Zhang X, Guo Y, Lin D. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28:1067-73.
37. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907-20.
38. Hanane L, Natarajan A, Sieghart W, Sibilia M. EGFR has a tumourpromoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol 2014;16.972.
39. Champiat S, Ferte C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014;3:e27817.
40. Fuertes MB, Kacha AK, Kline J, Woo SR, Murphy KM, Gajewski TF, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med 2011;208:2005-16.
41. Woo SR, Fuertes MB, Alegre ML, Gajewski TF. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014;41:830-42.
42. Leong EJ, Pardoll D, Dubensky T. Modified STING-activating cyclic dinucleotide derivatives significantly enhance the anti-tumor activity of therapeutic vaccines. J ImmunoTherapy Cancer 2013;1.Suppl 1: O20.
43. Sangro B, Carlos GM, De La Mata M, Inarrairaegui M, Perez-Gracia JL, Melero I, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.